GlycoMimetics Inc (GLYC)vsModerna Inc (MRNA)
GLYC
GlycoMimetics Inc
$0.16
0.00%
HEALTHCARE · Cap: $10.13M
MRNA
Moderna Inc
$143.97
+5.38%
HEALTHCARE · Cap: $56.02B
Smart Verdict
WallStSmart Research — data-driven comparison
Moderna Inc generates 22279900% more annual revenue ($2.23B vs $10,000). GLYC leads profitability with a 0.0% profit margin vs -141.4%. MRNA earns a higher WallStSmart Score of 21/100 (F).
GLYC
Avoid17
out of 100
Grade: F
MRNA
Avoid21
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for GLYC.
Margin of Safety
+70.0%
Fair Value
$134.97
Current Price
$143.97
$9.00 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Large-cap with strong market position
Conservative balance sheet, low leverage
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Operating margin of 0.0%
Trading at 8.5x book value
2.1% revenue growth
Weak financial health signals
ROE of -46.6% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : GLYC
The strongest argument for GLYC centers on Price/Book.
Bull Case : MRNA
The strongest argument for MRNA centers on Market Cap, Debt/Equity.
Bear Case : GLYC
The primary concerns for GLYC are EPS Growth, Market Cap, Profit Margin.
Bear Case : MRNA
The primary concerns for MRNA are Price/Book, Revenue Growth, Piotroski F-Score.
Key Dynamics to Monitor
GLYC profiles as a value stock while MRNA is a turnaround play — different risk/reward profiles.
GLYC carries more volatility with a beta of 1.60 — expect wider price swings.
MRNA is growing revenue faster at 2.1% — sustainability is the question.
MRNA generates stronger free cash flow (-563M), providing more financial flexibility.
Bottom Line
MRNA scores higher overall (21/100 vs 17/100). Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
GlycoMimetics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of new glucomimetic drugs to address unmet medical needs resulting from disease in the United States. The company is headquartered in Rockville, Maryland.
Moderna Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. The company is headquartered in Cambridge, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?